Genprex, Inc. Files 8-K Report
Ticker: GNPX · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1595248
Sentiment: neutral
Topics: 8-K, filing, regulatory
Related Tickers: GNPX
TL;DR
Genprex filed an 8-K. Standard update, no major news yet.
AI Summary
On August 18, 2025, Genprex, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific new events, financial figures, or material agreements were detailed in the provided excerpt.
Why It Matters
This filing serves as an official notification to investors and the public about significant company events or financial updates, providing transparency into Genprex, Inc.'s operations.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report without specific material events detailed in the excerpt, suggesting no immediate new risks.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- August 18, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Genprex, Inc.?
The 8-K filing is a current report required by the SEC to announce material events or financial updates, serving as official notification to investors and the public.
What specific 'Other Events' are detailed in this filing?
The provided excerpt of the 8-K filing does not detail specific 'Other Events'; it only lists the item category.
Are there any new financial statements or exhibits mentioned in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the excerpt does not provide details on what these specific statements or exhibits are.
What is Genprex, Inc.'s principal executive office address?
Genprex, Inc.'s principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the filing date of this 8-K report?
The 8-K report was filed on August 18, 2025.
Filing Stats: 1,181 words · 5 min read · ~4 pages · Grade level 14.5 · Accepted 2025-08-18 09:29:35
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20250815_8k.htm (8-K) — 33KB
- 0001437749-25-027191.txt ( ) — 165KB
- gnpx-20250818.xsd (EX-101.SCH) — 3KB
- gnpx-20250818_def.xml (EX-101.DEF) — 12KB
- gnpx-20250818_lab.xml (EX-101.LAB) — 15KB
- gnpx-20250818_pre.xml (EX-101.PRE) — 12KB
- gnpx20250815_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On August 18, 2025, Genprex, Inc. ("Genprex" or the "Company") issued a press release in which it announced that the U.S. Patent and Trademark Office has issued a notice of allowance for a patent to Genprex that covers the use of the Company's lead drug candidate, Reqorsa (quaratusugene ozeplasmid) Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq. Additionally, the European Patent Office has issued a notice of allowance to Genprex for a patent covering the use of REQORSA in combination with PD-1 antibodies. Both patents will expire in 2037 at the earliest. The press release also noted that Genprex has been granted patents for the use of REQORSA in combination with PD-L1 antibodies in Korea. Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China and Israel. Should these applications grant, they would be applicable to Genprex's Acclaim-3 clinical trial. Genprex has been granted patents for the use of REQORSA in combination with PD-1 antibodies in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Korea and Singapore. PD-L1 and PD-1 antibodies are a type of targeted immunotherapy and a part of a group of checkpoint inhibitor anti-cancer drugs that block the activity of PD-L1 and PD-1 immune checkpoint proteins present on the surface of cells. The Acclaim-3 study is a Phase 1/2 clinical trial that uses a combination of REQORSA and Genentech's Tecentriq as maintenance therapy for patients with extensive stage small cell lung cancer ("ES-SCLC") who are candidates for maintenance therapy after receiving Tecentriq and chemotherapy as initial standard treatment. The Acclaim-3 clinical trial has received U.S. Food and Drug Administration ("FDA") Fast Track Designation for this patient population, and Acclaim-3 has received FDA Orphan Drug Designation. Cautionary Language Concerning Forward-Looking Statements
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: August 18, 2025 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)